14th Pharmacovigilance 2017

 CONFERENCE INTRODUCTION:-

The Pharmacovigilance conference, organised yearly by Virtue Insight, is a unique event where key stakeholders gather with the aim of promoting patient safety and undertaking to continue work towards a more efficient pharmacovigilance system. In the spirit of constructive cooperation, this event brings together representatives from the industry and regulators as well as healthcare professionals and patient organisations.

In order to succeed in this new environment, it is critical to be up to date on legislation globally and be transparent in all PV process. We need to have effective systems in place to empower patients, physicians, drug manufacturers and consumers to make the best drug safety decisions.

14th Pharmacovigilance 2017 will bring together key thought leaders and experts to explore these worldwide challenges. This is your opportunity to engage and sit alongside the pioneers who are driving forward innovation in pharmacovigilance. Explore benefit-risk management strategies and patient-centric approaches; discuss how you can tackle the challenges of social media and drug safety legislation globally.

Morning sessions reflect on achievements so far and focus on the milestones ahead. An open dialogue between key stakeholders has proven to be the right approach for making significant progress towards better pharmacovigilance for better public protection. Traditional afternoon brainstorming sessions stimulate a lively, engaging debate incorporating all perspectives. Hot topics are debated to identify the best possible processes and tools leading to better access to high quality medicines in India.

It gives us immense pleasure in welcoming you to the 14th Pharmacovigilance 2017

KEY THEMES DISCUSSED AT THIS CONFERENCE:- 

• • PV legislation: What are the next steps? Reflections from the commission, IMA and the industry.
  • How to improve pharmacovigilance activities?
  • Creating a PV-focused culture
  • How can you achieve pragmatism environment in today's PV?
  • Pharmacovigilance and enabling technologies: which business model in a fast changing world?
  • Opportunity that can reduce financial risk and increase effectiveness
  • Pharmacovigilance Inspection Readiness
  • Risk Minimization and effectiveness evaluation
  • Business partners and exchange of safety data
  • Optimising Drug Safety through Research Based Pharmacovigilance
  • Launching a digital app in India for reporting ADRs: first results
  • PV automation for data processing - Can Artificial Intelligence be trusted
  • How social media can be used for pharmacovigilance syste
  • Barriers to adopting AI and automation
  • Patient view: the influence of real-time patient ratings and reviews of medicines and healthcare, and how this will shape the future of pharmacovigilance
  • Proactively accomplish drug safety through patient engagement
  • The challenges of the Indian Regulation – How to adapt and when?
  • Required undergo registration process with CDSCO & DCGI
  • Accelerating new medicine introduction in developing world & overcoming challenges
  • Be part of a major networking opportunity
  • KEY SPEAKERS:-

  v O S SADHWANI, Drug controller of Maharashtra and Jt.Commissioner Drug, FDA

  v K. BANGARURAJAN, Deputy Drugs Controller, DDC(I), CDSCO

  v MUZAFFAR AHMAD, Member, Strategic Advisory Board on Health Millenium Alliance (Govt of India) and Member Council of India

  v DAARA B. PATEL, Secretary General, Indian Drug Manufacturers' Association

  v DEEPA ARORA, Vice President - Pharmacovigilance & Global Head - Drug Safety & Risk Management, Lupin

  v JEAN-CHRISTOPHE DELUMEAU, Head of Pharmacovigilance Asia-Pacific, Bayer HealthCare (Singapore)

  v MANISH VERMA, Director and Head of Medical Affairs, South Asia Zone, Sanofi

  v AMBRISH SRIVASTAVA, Vice President: Medial Affairs,Clinical Research & Regulatory, Alkem Laboratories

  v VIKRAM GOTA, Associate Professor, ACTREC, Tata Memorial Centre

  v BHASWAT CHAKRABORTY, Senior VP & Chair, Research and Development Core Committee, Cadila

  v AVINASH R. KAKADE, Senior Director and Head of Pharmacovigilance, Cipla

  v SHUBHADEEP SINHA, Vice-President & Head (Global) - Clinical Development, Medical Affairs & Pharmacovigilance, Hetero Labs

  v RAHUL GUPTA, Vice President, Regulatory Affairs, USV

  v SUJAY SURESH KULKARNI, Senior Manager, Medical and Regulatory Affairs, GSK

  v MILIND ANTANI, Partner In-Charge - Pharma LifeSciences, Nishith Desai Associates

  v ABHAY PHANSALKAR, Head Clinical Trials, Cipla

  v DEEPTI SANGHAVI, Assistant Manager-Medical Writing, Tata Consultancy Services

  v RUCHIKA SINGHAL, Business Unit Head, AstraZeneca

  v GURPREET SINGH, Head of Vendor Management in PV, Novartis

  v NIDHI VAISH DAS, Drug Safety, Roche Pharmaceuticals

  v MANOJ SWAMINATHAN, Chief Manager / Head - Global Pharmacovigilance, Piramal

  v SHASHIDHAR SWAMY, Project Manager, Tata Consultancy Services

  v PRANJAL BORDOLOI, AVP - Medical Affairs and Pharmacovigilance, Veeda Clinical Research

  v RAJANI ROKADE, Founder-Director, PharmaSoulz

  v PRASHANT BODHE, Director, CliniSearch

  Plus Many More coming soon...

  WHO SHOULD ATTEND:-

  Vice Presidents, Directors, CRO’s, Heads and Managers of:

  • Pharmacovigilance Strategy
  • Drug Safety/Risk Management
  • Information and Clinical Data Management
  • Clinical Research
  • Research & Development
  • Product Safety/Assurance Assessment
  • Patient Safety & Outcomes Research & Data Analysis
  • Epidemiology project management
  • Regulatory Affairs and Compliance
  • Sales & Marketing
  • Biotech manufacturers

  From the following:

  • Pharmaceutical organizations
  • Generic pharmaceutical companies
  • Contract research organizations
  • Patient recruitment companies
  • Government- Department of health
  • Non-profit organizations/ Association
  • Consultants

  WHY SHOULD YOU ATTEND?

  Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

  CONFERENCE BOOKING DETAILS:-

  Early Bird Discounted Price – 1 Delegate Pass - (INR 6,000 + GST (18%) per delegate) - Book and Pay before 26th September 2017 to avail the early bird discounted price

  Standard Price (27th September 2017 Onwards) – 1 or 2 Delegates - (INR 7,000 + GST (18%) per delegate)

  Group Discounts – 3 or 4 Delegates - (INR 6,500 + GST (18%) per delegate)

  Group Discounts – 5 and above Delegates - (INR 6,000 + GST (18%) per delegate)

  Conference Sponsor & Exhibition Stall - We also have sponsorship opportunities available for the event which gives you an opportunity to speaker/exhibitor and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. So kindly let me know if you would be interested in sponsorship packages for speaking opportunity or exhibiting at the conference, you can simply email your interest and queries to TEL: +91 44 64614333, or fen@virtueinsight.co.in

  DELEGATE REGISTRATION PROCESS:-

  In order to register simply fill in the last page of the attached file and email is back to me or you can simply email me your invoice details in the below mentioned format;

  Company Name & Address:

  Attendee Name:

  Job Title:

  Contact Number:

  Should you and your colleagues wish to participate as our delegate kindly let me know on the same and I can help you with the same.

  If you require any further information then please do let me know. I look forward to hearing back from you soon.